Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 41OTHER 20NIH 3OTHER_GOV 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Pathologic Complete Response 1

Interventions

Radiotherapy 10Cisplatin 9Carboplatin 7Capecitabine 6Neoadjuvant Therapy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Paclitaxel 4Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Surgical Procedures, Operative 3Oxaliplatin 3Hydralazine 3Etoposide 3Drug Therapy 3pertuzumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2endostar protein 2Valproic Acid 2Tranexamic Acid 2Temozolomide 2TP protocol 2Saline Solution 2Radiotherapy, Adjuvant 2Radiation 2Proton Pump Inhibitors 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × pertuzumab × Clear all
NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Henan Cancer Hospital

Phase 3 Recruiting
812 enrolled
Breast

Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡